1. Protein Tyrosine Kinase/RTK
  2. c-Met/HGFR

c-Met/HGFR

c-Met (hepatocyte growth factor receptor, HGFR) is a protein possesses tyrosine kinase activity. The primary single chain precursor protein is post-translationally cleaved to produce the alpha and beta subunits, which are disulfide linked to form the mature receptor. c-Met is a membrane receptor that is essential for embryonic development and wound healing. Hepatocyte growth factor (HGF) is the only known ligand of the c-Met receptor. c-Met is normally expressed by cells of epithelial origin, while expression of HGF is restricted to cells of mesenchymalorigin. Upon HGF stimulation, c-Met induces several biological responses that collectively give rise to a program known as invasive growth.

c-Met/HGFR Related Products (33):

Cat. No. Product Name Effect Purity
  • HY-50878
    Crizotinib Inhibitor 99.77%
    Crizotinib is a potent inhibitor of c-Met and ALK with IC50 of 11 nM and 24 nM in cell-based assays, respectively.
  • HY-13016
    Cabozantinib Inhibitor 99.89%
    Cabozantinib is a potent multiple RTKs inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC50 of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.
  • HY-12076
    BMS 777607 Inhibitor 98.32%
    BMS 777607 is a Met-related inhibitor for c-Met, Axl, Ron and Tyro3 with IC50s of 3.9 nM, 1.1 nM, 1.8 nM and 4.3 nM, respectively, and 40-fold more selective for Met-related targets than Lck, VEGFR-2, and TrkA/B, with more than 500-fold greater selectivity versus all other receptor and non receptor kinases.
  • HY-50686
    Tivantinib Inhibitor 99.69%
    Tivantinib is a novel and highly selective c-Met tyrosine kinase inhibitor with Ki of 355 nM.
  • HY-10338
    Foretinib Inhibitor 99.81%
    Foretinib is an ATP-competitive inhibitor of HGFR and VEGFR, with IC50 of 0.4 nM and 0.9 nM for Met and KDR, less potent against Ron, Flt-1/3/4, Kit, PDGFRα/β and Tie-2, and has little activity to FGFR1 and EGFR.
  • HY-100946
    CEP-40783 Inhibitor
    CEP-40783 is a potent, selective and orally available inhibitor of AXL and c-Met with IC50 values of 7 nM and 12 nM, respectively.
  • HY-15514
    LY2801653 Inhibitor 99.71%
    LY2801653 is a type-II ATP competitive, slow-off inhibitor of MET tyrosine kinase with a dissociation constant (Ki) of 2 nM.
  • HY-13404
    INCB28060 Inhibitor 99.78%
    INCB28060 is a potent and selective c-MET kinase inhibitor. INCB28060 inhibits c-MET kinase activity with an average IC50 of 0.13 nM.
  • HY-15959
    Savolitinib Inhibitor 99.78%
    Savolitinib(Volitinib; AZD-6094; Volitinib) is an orally bioavailable inhibitor of the c-Met receptor tyrosine kinase(IC50= 5 nM) with potential antineoplastic activity.
  • HY-18696
    AMG-337 Inhibitor 99.19%
    AMG-337 is a potent and highly selective small molecule ATP-competitive MET kinase inhibitor. AMG 337 inhibits MET kinase activity with an IC50 of < 5nM in enzymatic assays.
  • HY-11107
    PHA-665752 Inhibitor 99.27%
    PHA-665752 is a potent, selective and ATP-competitive c-Met inhibitor with IC50 of 9 nM, >50-fold selectivity for c-Met than RTKs or STKs.
  • HY-15240
    c-Kit-IN-1 Inhibitor 98.71%
    c-Kit-IN-1 is a potent inhibitor of c-Kit and c-Met with IC50s of <200 nM.
  • HY-15514A
    LY2801653 dihydrochloride Inhibitor 99.59%
    LY2801653 dihydrochloride is a type-II ATP competitive, slow-off inhibitor of MET tyrosine kinase with a dissociation constant (Ki) of 2 nM.
  • HY-50878A
    Crizotinib hydrochloride Inhibitor 99.74%
    Crizotinib Hcl(PF-2341066) is a potent inhibitor of c-Met and ALK with IC50 of 11 nM and 24 nM, respectivley.
  • HY-12019
    SGX-523 Inhibitor 99.21%
    SGX-523 is a selective Met inhibitor with IC50 of 4 nM, no activity to BRAFV599E, c-Raf, Abl and p38α.
  • HY-12014
    SU11274 Inhibitor 98.56%
    SU11274 is a selective Met inhibitor with IC50 of 10 nM, but has no effects on PGDFRβ, EGFR or Tie2
  • HY-14721
    EMD-1214063 Inhibitor 99.31%
    EMD 1214063 is a potent and selective c-Met inhibitor with IC50 of 4 nM, >200-fold selective for c-Met than IRAK4, TrkA, Axl, IRAK1, and Mer.
  • HY-12017
    PF-04217903 Inhibitor 99.2%
    PF-04217903 is a selective ATP-competitive c-Met inhibitor with IC50 of 4.8 nM, susceptible to oncogenic mutations (no activity to Y1230C mutant).
  • HY-13299
    MK-8033 Inhibitor
    MK8033 is a novel and specific dual ATP competitive c-Met/Ron inhibitor (IC50=1 nM Wt c-Met) under investigation as a treatment for cancer.
  • HY-50683
    JNJ-38877605 Inhibitor 99.96%
    JNJ-38877605 is an ATP-competitive inhibitor of c-Met with IC50 of 4 nM, 600-fold selective for c-Met than 200 other tyrosine and serine-threonine kinases.